Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05592990 | A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy | PHASE2 | COMPLETED | 45 | — | — | Jun 14, 2023 | Feb 3, 2026 | Mar 30, 2026 | 7 | United States, France +1 |
AEs and SAEs including ECG parameters, Lab Chemistry and Hematology parameters, urinalysis, local tolerability
| Arm | Type | Description |
|---|---|---|
| NGI226 | EXPERIMENTAL | single peritendon injection |
| Placebo | PLACEBO_COMPARATOR | single peritendon injection |
| Name | Type | Description |
|---|---|---|
| NGI226 | DRUG | NGI226 MP |
| Placebo | DRUG | Placebo MP |
Inclusion Criteria: * Written informed consent must be obtained prior to all study specific screening procedures, as close to the start of the screening period as possible. * Presence of clinically (local Achilles tendon pain on tendon-loading activities, pain on palpation at the level 2-6 cm proxi...